Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma

被引:27
作者
Sánchez, R [1 ]
Espinosa-de-los-Monteros, A [1 ]
Mendoza, V [1 ]
Brea, E [1 ]
Hernández, I [1 ]
Sosa, E [1 ]
Mercado, M [1 ]
机构
[1] Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo 21, IMSS, Serv Endocrinol,Unidad Invest Med & Endocrinol Ex, Mexico City, DF, Mexico
关键词
thyroid carcinoma; TSH; thyroglobulin; levothyroxine; radioiodine scan;
D O I
10.1016/S0188-4409(02)00394-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. In the follow-up of patients with well-differentiated thyroid carcinomas (WTC), a thyroid-stimulating hormone (TSH) greater than or equal to30 muU/mL is generally accepted as adequate to perform whole body scans (WBS), determine thyroglobulin (Tg), and administer radioiodine therapeutically. These patients, inevitably rendered hypothyroid, are traditionally switched to T3 for 3-4 weeks prior to withdrawing all thyroid hormones for an additional 2-3 weeks. Neither TSH and Tg elevation dynamics nor WBS characteristics after simply interrupting L-T4 treatment without T3 administration have been evaluated. Methods. TSH, total T4 and T3, as well as FT4 were measured weekly after discontinuing L-T4 in 21 subjects (group 1) and after thyroidectomy in 10 subjects (group II). WBS and Tg determination was performed upon achievement of TSH greater than or equal to30 muU/mL. Results. By the second week, 42% of group I patients and 70% of group II patients had TSH greater than or equal to30 muU/mL. By the third week, 90% in group I and 1,00% in group II had achieved this target. Group I patients who needed 4 weeks to increase TSH received a greater cumulative radioiodine dose and had higher Tg levels. Positive WBS were found in eight cases and the incidence of a negative WBS with elevated Tg was significantly higher when evaluation occurred at the second week of L-T4 withdrawal compared to the fourth week. Conclusions. L-T4 interruption is a reasonable alternative to temporary T3 in preparation for radioiodine scanning and treatment. (C) 2002 IMSS. Published by Elsevier Science Inc.
引用
收藏
页码:478 / 481
页数:4
相关论文
共 11 条
[1]  
Chopra IJ, 2000, WERNER INGBARS THYRO, P121
[2]   MEASUREMENT OF SERUM TSH AND THYROID-HORMONES IN MANAGEMENT OF TREATMENT OF THYROID-CARCINOMA WITH RADIOIODINE [J].
EDMONDS, CJ ;
KERMODE, JC ;
HAYES, S ;
THOMPSON, BD .
BRITISH JOURNAL OF RADIOLOGY, 1977, 50 (599) :799-807
[3]   INFLUENCE OF TRIIODOTHYRONINE WITHDRAWAL TIME ON I-131 UPTAKE POST-THYROIDECTOMY FOR THYROID-CANCER [J].
GOLDMAN, JM ;
LINE, BR ;
AAMODT, RL ;
ROBBINS, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 50 (04) :734-739
[4]   Moderate hypothyroidism in preparation for whole body I-131 scintiscans and thyroglobulin testing [J].
Guimaraes, V ;
DeGroot, LJ .
THYROID, 1996, 6 (02) :69-73
[5]  
HAMBURGER JI, 1979, J NUCL MED, V21, P492
[6]   A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer [J].
Haugen, BR ;
Pacini, F ;
Reiners, C ;
Schlumberger, M ;
Ladenson, PW ;
Sherman, SI ;
Cooper, DS ;
Graham, KE ;
Braverman, LE ;
Skarulis, MC ;
Davies, TF ;
DeGroot, LJ ;
Mazzaferri, EL ;
Daniels, GH ;
Ross, DS ;
Luster, M ;
Samuels, MH ;
Becker, DV ;
Maxon, HR ;
Cavalieri, RR ;
Spencer, CA ;
McEllin, K ;
Weintraub, BD ;
Ridgway, EC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :3877-3885
[7]  
HILTS SV, 1979, J NUCL MED, V20, P928
[8]   Current approaches to primary therapy for papillary and follicular thyroid cancer [J].
Mazzaferri, EL ;
Kloos, RT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1447-1463
[9]   Clinical use of recombinant human TSH in thyroid cancer patients [J].
Schlumberger, M ;
Ricard, M ;
Pacini, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 (05) :557-563
[10]   Medical progress - Papillary and follicular thyroid carcinoma [J].
Schlumberger, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :297-306